OPKO HEALTH, INC. (OPK) — Inside-Filings

Sentiment-Signal

6,5

Stark Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (19.03.2026)

Datum	Meldung	Schwere	Filing	Auszug
19.03.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
29.05.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
29.07.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C
09.02.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C
19.05.2023	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C

Stammdaten

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Unternehmen & Branche

Name	OPKO HEALTH, INC.
Ticker	OPK
CIK	0000944809
Boerse	US
Sektor	Healthcare
Industrie	Medical - Diagnostics & Research
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	836,8 Mio. USD
Beta	1,49
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	606,879,000	-225,680,000	-0.30	1,931,944,000	1,267,959,000
2025-09-30	10-K	151,669,000	21,631,000	0.03
2025-09-30	10-Q	151,669,000	21,631,000	0.03	1,995,508,000	1,305,490,000
2025-06-30	10-K	156,807,000	-148,441,000	-0.19
2025-06-30	10-Q	156,807,000	-148,441,000	-0.19	1,972,989,000	1,296,904,000
2025-03-31	10-Q	149,952,000	-67,613,000		2,128,327,000	1,311,663,000
2025-03-31	10-K	149,952,000	-67,613,000	-0.10
2024-12-31	10-K	183,638,000	14,027,000	0.01	2,200,212,000	1,365,448,000
2024-09-30	10-Q	173,632,000	24,890,000	0.03	2,256,103,000	1,403,417,000
2024-09-30	10-K	173,632,000	24,890,000	0.03
2024-06-30	10-Q	182,186,000	-10,305,000	-0.01	1,979,871,000	1,395,317,000
2024-06-30	10-K	182,186,000	-10,305,000	-0.01
2024-03-31	10-K	173,686,000	-81,836,000	-0.12
2024-03-31	10-Q	173,686,000	-81,836,000		1,974,016,000	1,252,808,000
2023-12-31	10-K	181,905,000	-66,483,000	-0.25	2,011,698,000	1,389,219,000
2023-09-30	10-Q	178,595,000	-84,473,000	-0.11	2,056,680,000	1,444,568,000
2023-09-30	10-K	178,595,000	-84,473,000
2023-06-30	10-K	265,418,000	-19,640,000
2023-06-30	10-Q	265,418,000	-19,640,000		2,158,899,000	1,535,348,000
2023-03-31	10-K	237,577,000	-18,267,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-20	PAGANELLI JOHN A	Director	Open Market Purchase	10,000	1.14	11,350.00	+9,7%
2025-11-21	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	192,870	1.34	257,481.45	+220,1%
2025-11-21	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	191,490	1.33	254,681.70	+217,7%
2025-11-21	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	102,371	1.30	133,082.30	+113,8%
2025-11-21	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	89,375	1.33	118,421.88	+101,2%
2025-11-21	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	3,894	1.32	5,140.08	+4,4%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	1,757	1.35	2,363.17	+2,0%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	211,948	1.33	281,890.84	+241,0%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	161,818	1.34	216,027.03	+184,7%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	119,129	1.32	157,250.28	+134,4%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	47,105	1.33	62,414.13	+53,4%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	24,579	1.34	32,935.86	+28,2%
2025-11-20	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	13,664	1.35	18,446.40	+15,8%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	36,325	1.28	46,496.00	+39,8%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	300	1.29	387.00	+0,3%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	12,993	1.31	16,955.87	+14,5%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	21,236	1.30	27,500.62	+23,5%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	30,082	1.30	39,106.60	+33,4%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	58,160	1.29	74,735.60	+63,9%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	66,504	1.31	87,120.24	+74,5%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	155,496	1.32	205,254.72	+175,5%
2025-11-19	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	198,904	1.32	261,558.76	+223,6%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	1	1.29	1.29	0,0%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	212,608	1.28	271,075.20	+231,7%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	83,556	1.29	107,369.46	+91,8%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	69,728	1.28	89,251.84	+76,3%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	66,635	1.26	83,626.93	+71,5%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	49,590	1.25	61,987.50	+53,0%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	33,572	1.29	43,307.88	+37,0%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	15,000	1.27	18,975.00	+16,2%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	1,772	1.27	2,250.44	+1,9%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	428	1.28	549.85	+0,5%
2025-11-18	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	410	1.25	510.45	+0,4%
2025-10-31	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	150,000	1.42	213,435.00	+182,5%
2025-08-08	FROST PHILLIP MD ET AL	Director, Officer, 10% Owner, CEO & Chairman	Open Market Purchase	675,000	1.32	891,000.00	+761,7%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.